We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ANSS
976
DELISTED
Ansys
ANSS
| $1.74M | ﹤0.01% |
4,966
-30,285
| -86% | -$9.92M |
|
977
Moog Inc Class A
MOG.A
$11.9B
| $1.74M | ﹤0.01% |
9,632
-363
| -4% | -$63.6K |
|
978
Jazz Pharmaceuticals
JAZZ
$15.9B
| $1.74M | ﹤0.01% |
16,402
+1,078
| +7% | +$117K |
|
979
Sabesp
SBS
$17.1B
| $1.73M | ﹤0.01% |
406,303
| – | – |
|
980
Establishment Labs
ESTA
$2.11B
| $1.73M | ﹤0.01% |
40,504
-1,433
| -3% | -$50K |
|
|
HDV
981
iShares Core High Dividend ETF
HDV
$15.2B
| $1.71M | ﹤0.01% |
72,800
-4,225
| -5% | -$97.4K |
|
982
Itron
ITRI
$4.27B
| $1.69M | ﹤0.01% |
12,827
-18,496
| -59% | -$2.09M |
|
983
BlueLinx
BXC
$624M
| $1.68M | ﹤0.01% |
22,635
-52
| -0.2% | -$3.63K |
|
|
KKR.PRD
984
KKR & Co 6.25% Series D Preferred Stock
KKR.PRD
$2.47B
| – | – |
0
| – | – |
|
985
Sensata Technologies
ST
$5.97B
| $1.66M | ﹤0.01% |
55,296
+41,133
| +290% | +$1.01M |
|
|
WNS
986
DELISTED
WNS Holdings
WNS
| $1.66M | ﹤0.01% |
+26,311
| New | +$1.58M |
|
987
Moelis & Co
MC
$5.07B
| $1.66M | ﹤0.01% |
26,571
-5,852
| -18% | -$328K |
|
988
Real REMAX Group Inc. Common Stock
REAX
$460M
| $1.63M | ﹤0.01% |
36,195
+30
| +0.1% | +$1.29K |
|
989
Payoneer
PAYO
$2.41B
| $1.63M | ﹤0.01% |
237,526
+189,900
| +399% | +$1.29M |
|
990
Apogee Enterprises
APOG
$842M
| $1.63M | ﹤0.01% |
40,038
-68
| -0.2% | -$2.81K |
|
991
DT Midstream
DTM
$13.2B
| $1.61M | ﹤0.01% |
14,634
-41
| -0.3% | -$4.15K |
|
992
Flowserve
FLS
$10.2B
| $1.6M | ﹤0.01% |
30,641
-5,367
| -15% | -$252K |
|
993
Unum
UNM
$14.7B
| $1.6M | ﹤0.01% |
19,814
+745
| +4% | +$58.8K |
|
994
PetMed Express
PETS
$40.8M
| $1.6M | ﹤0.01% |
481,434
+2,851
| +0.6% | +$10.2K |
|
995
Ardagh Metal Packaging
AMBP
$3.07B
| $1.59M | ﹤0.01% |
371,400
-29,535
| -7% | -$107K |
|
996
Avient
AVNT
$4.1B
| $1.59M | ﹤0.01% |
49,190
-16,476
| -25% | -$570K |
|
997
Constellium
CSTM
$3.66B
| $1.59M | ﹤0.01% |
+119,249
| New | +$1.34M |
|
998
United Natural Foods
UNFI
$2.77B
| $1.58M | ﹤0.01% |
67,689
+1,654
| +3% | +$43.1K |
|
999
Ironwood Pharmaceuticals
IRWD
$682M
| $1.56M | ﹤0.01% |
2,177,038
+871,676
| +67% | +$684K |
|
1000
Tenable Holdings
TENB
$4.15B
| $1.55M | ﹤0.01% |
45,928
-45,573
| -50% | -$1.48M |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.